Recombinant exendin 4 - Uni-Bio Science Group

Drug Profile

Recombinant exendin 4 - Uni-Bio Science Group

Alternative Names: Recombinant exendin-4 - Uni-Bio Science Group; Uni rE4; Uni-E4; Uni-E4-Fc

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Uni-Bio Science Group
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Jul 2009 Preclinical trials in Type-1 diabetes mellitus in China (SC)
  • 30 Jun 2009 Phase-III clinical trials in Type-2 diabetes mellitus in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top